Email: cspc@cspc.cn

Contact Us

CSPC Pharmaceutical Group Co., Ltd.

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL FOR NEW INDICATION

VOLUNTARY ANNOUNCEMENT FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL FOR NEW INDICATION

August 09, 2024

Previous: 2024 China Pharmaceutical Brand Value list: CSPC Pharma ranked sixth

Next: CSPC Subsidiary Won the First Prize of Provincial Science and Technology Progress Award

Phone:

+86 311 8703 7015

Email:

Legal terms Privacy protection

Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |